Warum Bitcoin als Wertspeicher in keinem diversifizierten Portfolio fehlen sollte. Jetzt lesen -w-
31.05.2017 23:20:00

Hemophilia A Therapeutics Pipeline (Hematological Disorders) Review H1 2017 Market Report

PUNE, India, May 31, 2017 /PRNewswire-iReach/ -- Therapeutic market research on Hemophilia A - Pipeline Review, H1 2017 adds in RnRMarketResearch.com.  The report provides an overview of the Hemophilia A (Hematological Disorders) pipeline landscape.  Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation.

Companies of the Hemophilia A Pipeline Market are Alnylam Pharmaceuticals Inc, Amarna Therapeutics BV, Apitope International NV , Bayer AG, BioMarin Pharmaceutical Inc, Bioverativ Inc, Catalyst Biosciences Inc, Chugai Pharmaceutical Co Ltd , CSL Ltd, DBV Technologies SA, Dimension Therapeutics Inc, Emergent BioSolutions Inc, EpiVax Inc, Expression Therapeutics LLC, Green Cross Corp, Idogen AB, Immusoft Corp, Lentigen Technology Inc, mAbxience SA, Novo Nordisk A/S, OPKO Biologics Ltd, Pangen Biotech Inc., Pfizer Inc, Pharming Group NV, Promethera Biosciences SA, rEVO Biologics Inc, Sangamo Therapeutics Inc, Shire Plc, SK Chemicals Co Ltd, Spark Therapeutics Inc, UniQure NV, XL-protein GmbH

Hemophilia A - Drug Profiles : ATXF-8117, BAX-888, BAY-1093884, BIVV-001, BMN-270, Cell Therapy to Target Coagulation Factor VIII for Hemophilia A, coagulation factor VIIa (recombinant), concizumab, CSL-689, damoctocog alfa pegol, Deimmunized FVIII, DTX-201, emicizumab, ET-3, fitusiran, Gene Therapy for Hematological Disorders, Gene Therapy for Hemophilia A, Gene Therapy to Activate Factor VIII for Hemophilia A, HepaStem, IN-3012, Kovaltry more..

Discount Available at http://www.rnrmarketresearch.com/contacts/discount?rname=1019659 .(This report is available at upto 25% Discount till June 02nd 2017.)

The Hemophilia A pipeline report provides a snapshot of the global therapeutic landscape of Hemophilia A (Hematological Disorders). The pipeline guide reviews pipeline therapeutics for Hemophilia A (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. The pipeline guide reviews key companies involved in Hemophilia A (Hematological Disorders) therapeutics and enlists all their major and minor projects. The pipeline guide evaluates Hemophilia A (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia A (Hematological Disorders).

 Order a copy of this research report athttp://www.rnrmarketresearch.com/contacts/purchase?rname=1019659.

Table of Contents:

List of Tables:

List of Figures
Number of Products under Development for Hemophilia A, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products by Targets, H1 2017
Number of Products by Stage and Targets, H1 2017
Number of Products by Mechanism of Actions, H1 2017
Number of Products by Stage and Mechanism of Actions, H1 2017
Number of Products by Routes of Administration, H1 2017
Number of Products by Stage and Routes of Administration, H1 2017
Number of Products by Top 10 Molecule Types, H1 2017
Number of Products by Stage and Top 10 Molecule Types, H1 2017

Related reports on Hemophilia:

Hemophilia B - Pipeline Review, H1 2017 : Hemophilia B - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Hemophilia B (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

About Us:

RnRMarketResearch.com is your one stop market research and industry analysis reports' library providing business data and intelligence information on thousands of micro markets with global as well as regional coverage. Category focused research, country reports, company profiles, regional and global industry profiles and guides to premium reports offering extensive coverage of other 20+ industries are all available in our library of syndicated market research reports.

Media Contact:Ritesh Tiwari, RnRMarketResearch.com, + 1 888 391 5441, sales@rnrmarketresearch.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com

SOURCE RnR Market Research

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!